CD19 Universal CAR-γδ T Cells

CD19 Universal CAR-γδ T Cells are an investigational cell therapy product in which γδ T cells are engineered to express a chimeric antigen receptor (CAR) targeting the B-lymphocyte antigen CD19. This approach combines the unique properties of γδ T cells, such as their innate-like cytotoxicity and reduced risk of graft-versus-host disease, with the targeted antitumor activity conferred by the anti-CD19 CAR. The therapy is being developed primarily for immune-mediated diseases and certain cancers, with current clinical trials focusing on active severe systemic lupus erythematosus (SLE). The mechanism of action involves recognition and lysis of CD19-expressing B cells through immunologic cytotoxicity, potentially leading to disease control in conditions driven by pathogenic B cells[2][3][8]. The developer is Guangzhou Bio-gene Technology.

Other names

CD19 γδ CAR T cells